

Historical Pharma Manufacturing Business





Historical Pharma Manufacturing Business

The Indian pharmaceutical industry has emerged as a global player in the past few decades, becoming one of the largest producers of generic drugs worldwide. The business of Indian pharmaceuticals has witnessed exponential growth, expanding its presence in both domestic and international markets.

The Indian pharmaceutical sector holds tremendous potential due to its vast pool of skilled professionals, cost-effective manufacturing capabilities, and large-scale production capacities. The country's strong research and development infrastructure further contribute to its success in the pharma business. India is home to several renowned pharmaceutical research institutions and has a robust regulatory framework to ensure quality standards are met.

The Indian pharmaceutical industry has achieved significant milestones in recent years. It has successfully developed and manufactured a wide range of generic drugs, thereby making healthcare more affordable and accessible globally. The affordability of Indian drugs has played a crucial role in providing healthcare solutions to developing nations, as well as contributing to the reduction of healthcare costs in developed countries.

India's expertise in producing high-quality generic drugs has also enabled it to become a major supplier of pharmaceutical products to countries around the world. Indian pharmaceutical firms have expanded their operations by establishing manufacturing facilities and research centers in various countries, allowing them to cater to the specific needs of different markets.

The pharma business in India has not only focused on generics but also made strides in pharmaceutical research and development. Several Indian companies have made significant investments in innovative drug discovery, with a strong focus on biotechnology and biosimilars. This has led to the development of breakthrough drugs for various diseases, enhancing India's reputation as a center for pharmaceutical innovation.

Overview

Multinational pharmaceutical company headquartered in India. It is one of the leading generic pharmaceutical companies in Asia, it operates in more than 30 countries and has a diverse portfolio of products ranging from prescription drugs to over-the-counter medications and active pharmaceutical ingredients.

The company is known for its strong research and development capabilities and has a reputation for manufacturing high-quality and affordable medicines. The company is committed to improving access to healthcare globally and strives to make a positive impact on people's lives through its innovative products and sustainable practices.

Currently the company do mostly Private Label, do not commercialize its own brand, but manufacture most of the common Pharmaceutical forms (Syrups, Capsules, Tablets, Powders, Lotions, solutions).

Keypoints

TARGET PRICE

\$1,050,000,000

GROSS REVENUE

\$306,500,000

EBITDA

\$87,500,000

BUSINESS TYPE

Pharma

REAL ESTATE

Included

COMPETITION

Lupin Limited, Cadila Healthcare, Torrent Pharmaceuticals, Aurobindo, Pharma, Biocon, Glenmark Pharmaceuticals, Alkem Laboratories

SUPPORT & TRAINING

24 months

REASON FOR SELLING

Carve Out

COUNTRY

India

BUSINESS ID

L#20240605

1. Focused on manufacturing and marketing generic drugs, active pharmaceutical ingredients (APIs), and custom pharmaceutical services.
2. The company has a diverse portfolio of products spanning various therapeutic categories, including cardiovascular, neurology, gastrointestinal, dermatology, and oncology.
3. Global presence and operates in more than 30 countries worldwide.
4. Strong focus on research and development, investing a significant portion of its revenues in R&D activities.
5. Dedicated team of scientists and researchers who work on developing new drug formulations and improving existing ones.
6. Robust pipeline of new products, with several filings and approvals in various countries.
7. Known for its emphasis on quality and compliance with international regulatory standards.
8. Several manufacturing facilities in India and abroad, which adhere to good manufacturing practices (GMP) guidelines.
9. Strong track record of successfully launching and marketing generic versions of blockbuster drugs globally.
10. Established partnerships and collaborations with leading pharmaceutical companies to access new molecules and markets.

KYC, POF REQUIRED

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM